Cat No:LP000057
Product Name: DMXAA,AS1404,ASA404
CAS NO:117570-53-3
Molecular Formula:C17H14O4
Molecular Weight:851.96300
Purity: ≥98%
Solubility: In DMSO
Storage: -10°C
DMXAA, the vascular disrupting agent, is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. DMXAA has no detrimental effect on 344SQ-ELuc cell viability. It is found that DMXAA-mediated up regulation of the NF-κB pathway as shown by increased p65 phosphorylation in M2 macrophages[1]. Results demonstrate that DMXAA-treated cells are protected from VSV-induced cytotoxicity at all MOIs in contrast to medium-pretreated macrophages. DMXAA effectively inhibits growth of both strains of influenza, demonstrating the potential of DMXAA for treatment of drug-resistant strains of human influenza.
344SQ-ELuc NSCLC subcutaneous tumors respond dramatically to DMXAA, with a marked decrease in bioluminescence (BLI) signals post-drug injection. DMXAA treatment of 344SQ-ELuc metastases yields no decrease in photon emission rates, with the tumors remaining histologically similar to controls after this treatment. As with the large subcutaneous tumors, DMXAA administration to mice with small subcutaneous tumors still leads to ~2-log decreases in photon emission at both 6 and 24 hours[1]. In vivo, DMXAA is a more potent inducer of IFN-β mRNA and a relatively poor inducer of TNF-α mRNA. DMXAA administration leads to significantly less weight loss in influenza-infected mice.
